摘要
目的比较瑞舒伐他汀与阿托伐他汀治疗重症冠心病急性心肌梗死的临床效果。方法选取2019年1月至2020年12月我院收治的96例重症冠心病急性心肌梗死患者为研究对象,按不同的治疗方案将其分为对照组(n=48)和观察组(n=48)。对照组采用阿托伐他汀钙片治疗,观察组采用瑞舒伐他汀钙片治疗。比较两组患者的治疗效果以及治疗前、治疗90 d后的血清炎症因子指标水平、动脉粥样硬化程度。结果观察组临床治疗总有效率显著高于对照组(P<0.05)。治疗90 d后,两组患者肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)、白介素-6(IL-6)、基质金属蛋白酶(MMP-9)水平较治疗前降低,且观察组低于对照组(P<0.05)。治疗90 d后,观察组的颈动脉内-中膜厚度小于对照组,冠状动脉狭窄程度评分、颈动脉斑块积分均低于对照组(P<0.05)。结论采用瑞舒伐他汀与阿托伐他汀治疗重症冠心病急性心肌梗死均能取得一定的治疗效果,但前者效果更佳,值得临床推广应用。
Objective To compare the clinical effects of rosuvastatin and atorvastatin in the treatment of severe coronary heart disease and acute myocardial infarction.Methods A total of 96 patients with severe coronary heart disease and acute myocardial infarction treated in our hospital from January 2019 to December 2020 were selected as the study objects,and the patients were divided into control group(n=48)and observation group(n=48)according to different treatment schemes.The control group was treated with atorvastatin calcium tablets,and the observation group was treated with rosuvastatin calcium tablets.The treatment effect and the levels of serum inflammatory factors indexes and the degree of atherosclerosis before and 90 d after treatment were compared between the two groups.Results The total effective rate of treatment of the observation group was significantly higher than that of the control group(P<0.05).After 90 d of treatment,the levels of tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),interleukin-6(IL-6)and matrix metalloproteinase-9(MMP-9)in the two groups were lower than those before treatment,and those in the observation group were lower than the control group(P<0.05).After 90 d of treatment,the carotid intima-media thickness in the observation group was less than that in the control group,and the coronary artery stenosis score and carotid plaque score were lower than those in the control group(P<0.05).Conclusion Rosuvastatin and atorvastatin in the treatment of severe coronary heart disease and acute myocardial infarction can achieve a certain treatment effect,but the former is better,which is worthy of clinical promotion and application.
作者
赵书琴
ZHAO Shuqin(No.4 Cardiology Department,the Second People's Hospital of Pingdingshan,Pingdingshan 467000,China)
出处
《临床医学研究与实践》
2022年第20期78-80,共3页
Clinical Research and Practice
关键词
瑞舒伐他汀
阿托伐他汀
冠心病
急性心肌梗死
rosuvastatin
atorvastatin
coronary heart disease
acute myocardial infarction
